Herceptin Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer
(Posted: 04/25/2005) - Results from two large randomized clinical trials for patients with HER-2 positive invasive breast cancer show that those patients with early-stage breast cancer who received Herceptin® (trastuzumab) in combination with chemotherapy had a significant decrease in risk for breast cancer recurrence compared with patients who received the same chemotherapy without trastuzumab.
www.cancer.gov
Herceptin Combined with Chemotherapy Has Benefits
Herceptin combined with chemotherapy controlled the cancer longer (almost 3 months more) and improved survival (about an additional 5 months) compared to the outcome for women in the chemotherapy-only groups.
www.breastcancer.org
